Biomedical Engineering Reference
In-Depth Information
28. McCown TJ, Xiao X, Li J et al (1996)
Differential and persistent expression patterns
of CNS gene transfer by an adeno-associated
virus (AAV) vector. Brain Res 713:99-107
29. Kay MA (2011) State-of-the-art gene-based
therapies: the road ahead. Nat Rev Genet
12:316-328
30. Kay MA, Glorioso JC, Naldini L (2001) Viral
vectors for gene therapy: the art of turning
infectious agents into vehicles of therapeutics.
Nat Med 7:33-40
31. Kells AP, Fong DM, Dragunow M et al (2004)
AAV-mediated gene delivery of BDNF or
GDNF is neuroprotective in a model of
Huntington disease. Mol Ther 9:682-688
32. Kirik D, Rosenblad C, Bjorklund A et al
(2000) Long-term rAAV-mediated gene trans-
fer of GDNF in the rat Parkinson's model:
intrastriatal but not intranigral transduction
promotes functional regeneration in the
lesioned nigrostriatal system. J Neurosci
20:4686-4700
33. McCarty DM, Monahan PE, Samulski RJ
(2001) Self-complementary recombinant
adeno-associated virus (scAAV) vectors pro-
mote effi cient transduction independently of
DNA synthesis. Gene Ther 8:1248-1254
34. Manfredsson FP, Rising AC, Mandel RJ
(2009) AAV9: a potential blood-brain barrier
buster. Mol Ther 17:403-405
35. Foust KD, Nurre E, Montgomery CL et al
(2009) Intravascular AAV9 preferentially tar-
gets neonatal neurons and adult astrocytes.
Nat Biotechnol 27:59-65
36. Duque S, Joussemet B, Riviere C et al
(2009) Intravenous administration of self-
complementary AAV9 enables transgene deliv-
ery to adult motor neurons. Mol Ther
17:1187-1196
37. Gray SJ, Matagne V, Bachaboina L et al (2011)
Preclinical differences of intravascular AAV9
delivery to neurons and glia: a comparative
study of adult mice and nonhuman primates.
Mol Ther 19:1058-1069
38. Shen F, Kuo R, Milon-Camus M et al (2013)
Intravenous delivery of adeno-associated viral
vector serotype 9 mediates effective gene
expression in ischemic stroke lesion and brain
angiogenic foci. Stroke 44:252-254
39. Xiao PJ, Lentz TB, Samulski RJ (2012)
Recombinant adeno-associated virus: clinical
application and development as a gene-therapy
vector. Ther Deliv 3:835-856
40. Smith AJ, Bainbridge JW, Ali RR (2012) Gene
supplementation therapy for recessive forms of
inherited retinal dystrophies. Gene Ther
19:154-161
41. Hauswirth WW, Aleman TS, Kaushal S et al
(2008) Treatment of Leber congenital amau-
rosis due to RPE65 mutations by ocular sub-
retinal injection of adeno-associated virus gene
vector: short-term results of a phase I trial.
Hum Gene Ther 19:979-990
42. Jacobson SG, Cideciyan AV, Ratnakaram R
et al (2012) Gene therapy for Leber congenital
amaurosis caused by RPE65 mutations: safety
and effi cacy in 15 children and adults followed
up to 3 years. Arch Ophthalmol 130:9-24
43. Banin E, Bandah-Rozenfeld D, Obolensky A
et al (2010) Molecular anthropology meets
genetic medicine to treat blindness in the
North African Jewish population: human gene
therapy initiated in Israel. Hum Gene Ther
21:1749-1757
44. Cideciyan AV, Hauswirth WW, Aleman TS
et al (2009) Human RPE65 gene therapy for
Leber congenital amaurosis: persistence of
early visual improvements and safety at 1 year.
Hum Gene Ther 20:999-1004
45. Haunstetter A, Izumo S (1998) Apoptosis:
basic mechanisms and implications for cardio-
vascular disease. Circ Res 82:1111-1129
46. Maguire AM, High KA, Auricchio A et al
(2009) Age-dependent effects of RPE65 gene
therapy for Leber's congenital amaurosis: a
phase 1 dose-escalation trial. Lancet 374:
1597-1605
47. Bainbridge JW, Smith AJ, Barker SS et al
(2008) Effect of gene therapy on visual func-
tion in Leber's congenital amaurosis. N Engl J
Med 358:2231-2239
48. Maguire AM, Simonelli F, Pierce EA et al
(2008) Safety and effi cacy of gene transfer for
Leber's congenital amaurosis. N Engl J Med
358:2240-2248
49. Hajjar RJ, Zsebo K, Deckelbaum L et al
(2008) Design of a phase 1/2 trial of intra-
coronary administration of AAV1/SERCA2a
in patients with heart failure. J Card Fail
14:355-367
50. Bowles DE, McPhee SW, Li C et al (2012)
Phase 1 gene therapy for Duchenne muscular
dystrophy using a translational optimized AAV
vector. Mol Ther 20:443-455
51. Miyagoe-Suzuki Y, Takeda S (2010) Gene
therapy for muscle disease. Exp Cell Res
316:3087-3092
52. DiPrimio N, McPhee SW, Samulski RJ (2010)
Adeno-associated virus for the treatment of
muscle diseases: toward clinical trials. Curr
Opin Mol Ther 12:553-560
53. Herzog RW, Cao O, Srivastava A (2010) Two
decades of clinical gene therapy—success is
fi nally mounting. Discov Med 9:105-111
Search WWH ::
Custom Search